Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05354570 · ClinicalTrials.gov registry record · Phase 2
A Study of Intensity-Modulated Pleural Radiation Therapy (IMPRINT) in People With Thymic Cancer That Has Spread to the Lining of the Lungs and Chest
A Phase 2 study of Pleural Metastases and Thymic Malignancies, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 7
- Study locations
NCT05354570: Recruiting Phase 2 study of Pleural Metastases and Thymic Malignancies, sponsored by Memorial Sloan Kettering Cancer Center.
NCT05354570 is a Phase 2 study of Pleural Metastases and Thymic Malignancies that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 36 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05354570, a Phase 2 study of Pleural Metastases and Thymic Malignancies, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 7
- Study locations
Study Summary
The researchers are doing this study to find out whether hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) is a safe treatment that causes few or mild side effects in people with pleural metastases from thymic malignancies. The researchers will also look at whether hemithoracic IMPRINT is effective against participants' cancer.
Primary Outcome
as indicated by the rate of grade 3 or higher radiation pneumonitis defined by the NCI Common Terminology Criteria (CTC) version 5.0.
Conditions Studied
Interventions
- RADIATION Intensity-Modulated Pleural Radiation Therapy (IMPRINT)
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk - Commack (Limited protocol activities) - Commack
- Memorial Sloan Kettering Westchester (Limited protocol activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Limited protocol activities) - Rockville Centre
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited protocol activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited protocol activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited protocol activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-04-26 |
| Est. Completion | 2026-04 |
| Phase | Phase 2 |
What NCT05354570 shows while recruiting
NCT05354570 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower).
The record links to 2 conditions, with Pleural Metastases appearing as the primary indexed condition, and to 1 intervention - of which Intensity-Modulated Pleural Radiation Therapy (IMPRINT) is the first listed.
NCT05354570 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT05354570 about?
NCT05354570 is a clinical study titled "A Study of Intensity-Modulated Pleural Radiation Therapy (IMPRINT) in People With Thymic Cancer That Has Spread to the Lining of the Lungs and Chest". The researchers are doing this study to find out whether hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) is a safe treatment that causes few or mild side effects in people with pleural metastases from thymic malignancies. The researchers will also look at whether hemithoracic IM...
What is the current status of trial NCT05354570?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2022-04-26. Estimated completion is 2026-04.
What conditions does trial NCT05354570 study?
This clinical trial studies the following conditions: Pleural Metastases, Thymic Malignancies.
What interventions are being tested in trial NCT05354570?
The interventions under investigation include: Intensity-Modulated Pleural Radiation Therapy (IMPRINT) (RADIATION).
Who is sponsoring clinical trial NCT05354570?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05354570 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pleural Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05354570's enrollment target sits among peer trials
36 1496th of 2000 higher than 478 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI